Home › Funds › CenterBook Partners LP › REGN

CenterBook Partners LP position in REGN

REGENERON PHARMACEUTICALS · Health Care

CenterBook Partners LP reported holding 15,486 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$9.7M, representing 0.47% of its reported portfolio and ranking #43 among its reported holdings. CenterBook Partners LP has disclosed REGN holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)15.49K sh
Reported value held$9.66M
Portfolio Weight0.47%
First reportedQ2 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How CenterBook Partners LP's REGN position evolved

CenterBook Partners LP first disclosed a stake in REGN in Q2 2024 at 4,718 shares (US$5.0M). The position peaked in Q3 2025 at 57,223 shares, worth US$32.2M. Across 9 filings, CenterBook Partners LP increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 15,486 shares valued at US$9.7M — an increase of 10,426 shares quarter over quarter.. Notable position changes include a 404% increase in Q3 2024 (shares fell 32% over the following quarter), a 803% increase in Q2 2025 (shares rose 8% over the following quarter), a 206% increase in Q2 2026 (shares rose 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 4.72K $4.96M New
Q3 2024 23.77K $24.99M Add
Q4 2024 15.98K $11.39M Reduce
Q1 2025 5.71K $3.62M Reduce
Q2 2025 51.59K $27.09M Add
Q3 2025 57.22K $32.17M Add
Q4 2025 30.25K $23.35M Reduce
Q1 2026 5.06K $3.91M Reduce
Q2 2026 15.49K $9.66M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has CenterBook Partners LP held REGN?

CenterBook Partners LP has disclosed REGN holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

What is CenterBook Partners LP's current position in REGN?

As of Q2 2026, CenterBook Partners LP holds 15.49K shares of REGN (REGENERON PHARMACEUTICALS), valued at $9.66M, representing 0.47% of its reported portfolio and ranking #43.

Has CenterBook Partners LP been buying or selling REGN?

In the latest 13F filing (Q2 2026), CenterBook Partners LP increased its position in REGN. The position peaked in Q3 2025 at 57.22K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.